Showing results (1-10 of 56) with videos related to
Sort By:
Pageof 6
Onkologie|June 14, 2008
[Concepts for clinical testing of biological agents exemplified for vaccines]Cedrik M BrittenMethods in Molecular Biology (Clifton, N.J.)|September 30, 2011
The impact of harmonization on ELISPOT assay performanceSylvia Janetzki, Cedrik M BrittenNature Reviews. Drug Discovery|April 9, 2021
Industrializing engineered autologous T cells as medicines for solid tumoursCedrik M Britten, Aiman Shalabi, Axel HoosCancer Immunology, Immunotherapy : CII|September 1, 2005
Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2Julia Steitz, Cedrik M Britten, Thomas Wölfel, et al.Methods in Molecular Biology (Clifton, N.J.)|September 30, 2011
Response determination criteria for ELISPOT: toward a standard that can be applied across laboratoriesZoe Moodie, Leah Price, Sylvia Janetzki, et al.Journal of Immunological Methods|May 26, 2005
Identification of T cell epitopes by the use of rapidly generated mRNA fragmentsCedrik M Britten, Ralf G Meyer, Claudine Graf, et al.Journal of Immunological Methods|April 22, 2004
The use of clonal mRNA as an antigenic format for the detection of antigen-specific T lymphocytes in IFN-gamma ELISPOT assaysCedrik M Britten, Ralf G Meyer, Nadine Frankenberg, et al.Vaccine|May 15, 2007
Rapid identification of an HLA-B*1501-restricted vaccinia peptide antigenRalf G Meyer, Claudine Graf, Cedrik M Britten, et al.Journal of Immunological Methods|December 4, 2001
The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assaysCedrik M Britten, Ralf G Meyer, Tanja Kreer, et al.Nature Protocols|June 26, 2015
Guidelines for the automated evaluation of Elispot assaysSylvia Janetzki, Leah Price, Helene Schroeder, et al.Pageof 6